Ibrutinib for treating relapsed or refractory mantle cell lymphoma - guidance (TA502)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
31 January 2018

Abstract

Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: January 2021